HomeCompareSYN vs ADC

SYN vs ADC: Dividend Comparison 2026

SYN yields 196.08% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $102.4K in total portfolio value· pulled ahead in Year 9
10 years
SYN
SYN
● Live price
196.08%
Share price
$1.02
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$74.42
Full SYN calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — SYN vs ADC

📍 ADC pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYN + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYN pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYN
Annual income on $10K today (after 15% tax)
$16,666.67/yr
After 10yr DRIP, annual income (after tax)
$63.26/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,614.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYN + ADC for your $10,000?

SYN: 50%ADC: 50%
100% ADC50/50100% SYN
Portfolio after 10yr
$127.7K
Annual income
$40,435.86/yr
Blended yield
31.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

SYN
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Altman Z
-14.5
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYN buys
0
ADC buys
0
No recent congressional trades found for SYN or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNADC
Forward yield196.08%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.4%
Portfolio after 10y$76.5K$178.9K
Annual income after 10y$74.42$80,797.29
Total dividends collected$34.4K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SYN vs ADC ($10,000, DRIP)

YearSYN PortfolioSYN Income/yrADC PortfolioADC Income/yrGap
1$20,504$9,803.92$10,990$580.36+$9.5KSYN
2$31,333$9,393.40$12,301$860.26+$19.0KSYN
3$40,234$6,707.62$14,104$1,298.62+$26.1KSYN
4$47,075$4,024.82$16,691$2,008.16+$30.4KSYN
5$52,570$2,200.55$20,580$3,205.09+$32.0KSYN
6$57,399$1,148.35$26,754$5,330.02+$30.6KSYN
7$62,003$585.89$37,196$9,345.14+$24.8KSYN
8$66,638$295.74$56,244$17,523.09+$10.4KSYN
9← crossover$71,452$148.53$94,286$35,736.21$22.8KADC
10$76,528$74.42$178,949$80,797.29$102.4KADC

SYN vs ADC: Complete Analysis 2026

SYNStock

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Full SYN Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this SYN vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYN vs SCHDSYN vs JEPISYN vs OSYN vs KOSYN vs MAINSYN vs NNNSYN vs EPRTSYN vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.